<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is characterized by loss of beta-cell mass and concomitant deposition of amyloid derived from islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> (IAPP) </plain></SENT>
<SENT sid="1" pm="."><plain>Previously we have shown that expression of human IAPP (huIAPP) in islets of transgenic mice results in either a rapid <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> in mice homozygous for the huIAPP transgene on a lean background (FVB/N) or a gradual <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> in mice hemizygous for the huIAPP transgene on an <z:mp ids='MP_0001261'>obese</z:mp> background (A(vy)/A) </plain></SENT>
<SENT sid="2" pm="."><plain>In both strains, only the males routinely develop <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>To investigate this sexual dimorphism, we treated young <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetic</z:e> A(vy)/A mice transgenic for huIAPP (huIAPP-A(vy)) with <z:chebi fb="0" ids="16469">17beta-estradiol</z:chebi> (E2) </plain></SENT>
<SENT sid="4" pm="."><plain>The treatment completely blocked the progression to <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> but also prevented the associated <z:mp ids='MP_0005456'>weight gain</z:mp> in these mice </plain></SENT>
<SENT sid="5" pm="."><plain>Immunohistochemistry of pancreatic sections demonstrated <z:mpath ids='MPATH_458'>normal</z:mpath> islet <z:mp ids='MP_0000002'>morphology</z:mp> with no apparent deposition of islet amyloid </plain></SENT>
<SENT sid="6" pm="."><plain>E2 treatment of 1-year-old huIAPP-A(vy) diabetic males rapidly reverses <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>To determine the effects of E2 in a nonobese model, we also treated <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetic</z:e>, ad libitum-fed and pair-fed Lean-huIAPP transgenic males </plain></SENT>
<SENT sid="8" pm="."><plain>E2 completely blocked the progression to <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> with no significant effect on body weight </plain></SENT>
<SENT sid="9" pm="."><plain>Pancreatic insulin content and plasma insulin concentration of Lean-huIAPP transgenic mice increased in a dose-dependent manner </plain></SENT>
<SENT sid="10" pm="."><plain>We demonstrated the presence of <z:chebi fb="0" ids="50114">estrogen</z:chebi> receptor (ER)-alpha <z:chebi fb="2" ids="33699">mRNA</z:chebi> in mouse and human islets </plain></SENT>
<SENT sid="11" pm="."><plain>By also confirming the presence of ER-alpha protein in islets, we discovered a novel 58-kDa ER-alpha isoform in mice and a 52-kDa isoform in humans, in the absence of the classic 67-kDa protein found in most tissues of both species </plain></SENT>
<SENT sid="12" pm="."><plain>The demonstrated presence of ER-alpha in mouse and human islets is consistent with a direct effect on islet function </plain></SENT>
<SENT sid="13" pm="."><plain>We conclude that exogenous E2 administered to male mice may block human IAPP-mediated beta-cell loss both by direct action on beta-cells and by decreasing insulin demand through inhibition of <z:mp ids='MP_0005456'>weight gain</z:mp> or increasing insulin action </plain></SENT>
</text></document>